Chugai Transfers MONILAC® Syrup Business to Maruishi

Chugai would join Maruishi in the business pertaining to the medication "MONILAC® Syrup 65%" (henceforth, MONILAC), which improves intestinal function physiologically and for which Chugai has the Japanese production and marketing permission.

Since 1975, Chugai has been selling MONILAC and disseminating information in Japan. Given the maturity of its product lifecycle, Chugai has been thinking about how it would sell itself domestically going forward. Following talks between Chugai and Maruishi, it was decided that Chugai would give Maruishi all of the assets related to MONILAC in Japan, including manufacturing and marketing permission as well as intellectual property rights like trademarks. Maruishi would then be in charge of MONILAC sales. With its expertise in the basic medicine space, Maruishi will work to optimise MONILAC's value by using its current product line in a complementary manner.

To complete the purchase, Maruishi and Chugai are moving forward with the required administrative and legal processes. The sales transfer procedure is expected to be finished by the end of February 2025. As soon as the sales transfer date is determined, we will notify the pertinent parties.To guarantee a steady supply and accomplish a seamless transfer of the marketing permission for MONILAC, Maruishi and Chugai will work together.